In a study of pancreatic cancer, by using the CRISPR/Cas9 system to disrupt C1GALT1 in human pancreatic ductal adenocarcinomas cells, the results showed enhanced invasiveness and metastatic ability of these cells and increased production of Tn (64). The gene discussed is C1GALT1; the disease is familial pancreatic carcinoma.